Trial Profile
A Pilot Study to Assess Disease State Stability, Efficacy, and Tolerability in a Natalizumab to Dimethyl Fumarate Crossover Design
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms IIT6
- 15 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 06 May 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov
- 06 May 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov